S&P 5007,785.76▼0.2% Nasdaq26,729.16▼0.3% Dow53,732.41▼0.2% Russell 2K3,068.42▲0.5% 10-Yr4.70%+6bp VIX14.25−0.38 WTI$82.40▲1.4% Gold$4,432.00▲1.6% EUR/USD1.157▲0.4% BTC$79,171▲0.3% Nikkei68,309▲1.2%
At close · Fri, Aug 14, 2026
Daily Market Updates.

Earnings

Home›Earnings›Results›Eli Lilly revenue jumps 48% as demand for GLP-1 drugs…

Eli Lilly revenue jumps 48% as demand for GLP-1 drugs rises

Lilly said sales growth was fueled by higher-than-expected demand for Mounjaro and Zepbound.

Reported · Written up by our desk · Results

Eli Lilly reported revenue growth of 48%, citing stronger demand for its GLP-1 therapies, Mounjaro and Zepbound, MarketWatch reported.

The drugs are used for Type 2 diabetes and weight loss, and the outlet said sales outperformance reflected demand that came in higher than expected.

The update highlights how Eli Lilly’s GLP-1 product demand continues to drive company performance.

← Newer storyAI agents used stolen identities to attempt malicious code approvals

More like this

EarningsDick's Sporting Goods shares plunge after management warns of pain ahead
EarningsPathward misses fiscal Q3 estimates as credit losses jump
EarningsLowe’s cuts outlook as organic growth stays near flat
EarningsDick's Sporting Goods shares drop 15% after Q2 earnings miss
EarningsLego revenue and profit rise as World Cup and F1 tie-ins boost sales

Sources

MarketWatchLilly’s revenue soars 48%, driven by demand for its GLP-1s
MarketWatchLilly’s revenue soars 48%, driven by demand for its GLP-1s

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.